➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Moodys
Medtronic
McKinsey
AstraZeneca

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 7,250,420

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 7,250,420
Title:Method of treatment of transplant rejection
Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above.
Inventor(s): Changelian; Paul S. (East Greenwich, RI)
Assignee: Pfizer Inc. (New York, NY)
Application Number:10/720,600
Patent Claims:see list of patent claims

Details for Patent 7,250,420

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 2017-05-26 ⤷  Free Forever Trial Pfizer Inc. (New York, NY) 2022-11-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
McKinsey
Harvard Business School
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.